Epilepsy device maker NeuroSigma withdraws $50 million IPO
NeuroSigma, which sells bio-electrical devices used to treat drug-resistant epilepsy and depression, withdrew its plans for an initial public offering on Monday. It postponed its $50 million IPO in October 2014.
The Los Angeles, CA-based company was founded in 2008. It had planned to list on the Nasdq under the symbol NSIG. NeuroSigma initially filed confidentially on 11/27/2013. Jefferies was set to be the sole bookrunner on the deal.
The article Epilepsy device maker NeuroSigma withdraws $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.